Alprostadil (Caverject/MUSE) Regret, Stopping, and Restarting: What Real Patients Experience

Why Men Regret Starting Alprostadil

Alprostadil produces reliable erections through a direct pharmacological mechanism, but patient regret is common enough that discontinuation rates in real-world practice run significantly higher than those seen in clinical trials. The gap exists because trial conditions involve trained staff, supervised titration, and close follow-up, none of which most outpatient prescriptions include.

Injection Anxiety Is the Leading Driver

Penile self-injection stops many men before they complete a second dose. A 1997 study by Porst published in the International Journal of Impotence Research (N=2,476) found that roughly 30% of men who received a Caverject prescription never filled a second one, with needle phobia listed as the primary reason in chart notes [1]. The anxiety is psychological, not physiological, but that distinction rarely helps in the moment.

Men on Reddit's r/erectiledysfunction frequently describe the same arc: they research the drug, feel confident, receive the starter kit, and then spend 20 minutes holding the syringe before giving up. The needle is short (5/8 inch, 27 to 30 gauge), and most users report that the injection itself is nearly painless once they commit. But "nearly painless once you commit" is cold comfort before the first attempt.

Penile Pain After Injection

Alprostadil itself causes a prostaglandin-mediated burning sensation in a subset of users. Published data place this figure at 11 to 37% depending on dose and population [2]. The pain typically peaks at 5 to 10 minutes post-injection and resolves as the erection fades, but men who experience it on their first attempt often stop entirely rather than asking for a dose reduction.

MUSE users report a different texture of discomfort: urethral burning and, occasionally, hypotension-related lightheadedness. A double-blind trial by Padma-Nathan et al. (N=1,511) in The New England Journal of Medicine reported that 32% of MUSE users reported penile pain and 3% experienced symptomatic hypotension [3].

First-Dose Failure and Dose Mismatch

Alprostadil is titrated to the individual. A starting dose that is too low produces a partial erection, enough to disappoint but not enough to use. That experience is demotivating even when it is clinically expected. The FDA-approved starting dose for Caverject in neurogenic ED is 1.25 mcg; for psychogenic or vasculogenic ED it is 2.5 mcg [4]. Many men receive a single starter dose without clear instruction that titration upward is both expected and necessary.

Who Actually Stops and When

The First-90-Day Window

Discontinuation clusters in the first 90 days of use. A long-term follow-up study by Chew et al. In BJU International (N=261 men, median follow-up 26 months) found that 64% of men who stopped alprostadil did so within the first three months, and the two leading reasons were pain (38%) and "lack of spontaneity" (29%) [5]. Only 9% stopped due to treatment failure defined as complete non-response.

That statistic matters. It suggests the majority of discontinuers are not pharmacological non-responders, they are patients whose experience could be improved with technique, dose, or delivery-route adjustments.

Partner-Related Discontinuation

Partners shape outcomes more than prescribers often anticipate. Some partners object to the clinical nature of injection-assisted sex. Others become anxious about priapism or vascular complications after reading package inserts. A qualitative analysis in the Journal of Sexual Medicine noted that partner non-acceptance was a significant factor in 22% of alprostadil discontinuations in their cohort [6]. Men who stopped for this reason rarely described physiological failures.

Priapism Fear vs. Actual Priapism

Fear of priapism (erection lasting over 4 hours) is cited far more often than actual priapism. Real-world priapism rates for properly titrated Caverject sit around 1% per the FDA label [4]. The MUSE label reports a figure under 0.1% [7]. Men who self-titrate upward without medical guidance face higher risk, which explains why community forums (Reddit, patient review boards) contain a disproportionate number of priapism anecdotes relative to clinical trial data.

The American Urological Association guideline on erectile dysfunction states: "Patients should be counseled that prolonged erections are rare when doses are titrated appropriately in a clinical setting and that immediate emergency care should be sought for any erection lasting more than 4 hours" [8].

Real-World Patient Experiences: What Forums and Reviews Reveal

Online communities and structured review platforms provide a qualitative picture that phase III trials cannot.

Common Positive Themes

Men who report satisfaction with alprostadil consistently describe one feature above all others: reliability. Unlike oral PDE5 inhibitors (sildenafil, tadalafil), alprostadil does not depend on sexual arousal to initiate the response. For men with severe vasculogenic ED or post-prostatectomy nerve damage, that reliability is a genuine clinical advantage. A Cochrane review comparing intracavernosal alprostadil with placebo found response rates between 70 to 80% across vasculogenic and psychogenic subtypes [9].

Posts on patient review platforms tend to describe alprostadil as "the thing that finally worked" after sildenafil and tadalafil failed. Men with diabetes or post-surgical nerve injury make up a large share of this group. PDE5 inhibitors require some intact nitric-oxide signaling; alprostadil bypasses that pathway entirely.

Common Negative Themes

Negative reviews cluster around four complaints: the injection process itself, post-erection penile aching, the absence of a spontaneous sexual context, and cost. Caverject Impulse 20 mcg dual-chamber syringes retail for roughly $85 to 130 per unit without insurance coverage, and most insurance plans require prior authorization after oral agents fail [4].

Men on Drugs.com give alprostadil an average rating around 7.5 out of 10, with reviewers who persist past the first month rating it substantially higher than those who do not. The pattern suggests a learning curve effect: satisfaction improves as injection technique becomes automatic.

What Reddit Users Say About MUSE Specifically

MUSE (alprostadil urethral suppository) receives notably more mixed reviews than Caverject in online communities. The advantage is obvious: no needle. The disadvantages are also obvious: lower efficacy, mandatory urination before insertion to lubricate the urethra, and a burning sensation that is harder to modulate than injection-site pain. The Padma-Nathan NEJM trial (N=1,511) found that 64.9% of MUSE patients had at least one successful intercourse attempt vs. 18.6% in the placebo group [3], but real-world figures are lower because in-home use lacks the vasodilatory benefit of the supine position used in the trial.

Several Reddit users describe MUSE as a "stepping stone", they start on MUSE to avoid needles, achieve partial results, and eventually move to Caverject when motivation for better outcomes outweighs needle aversion.

The Clinical Science of Stopping

What Happens Physiologically When You Stop

Alprostadil does not cause dependence. Stopping creates no withdrawal syndrome and does not worsen the underlying erectile dysfunction. The mechanism is purely local: alprostadil stimulates adenylyl cyclase, raises intracellular cyclic AMP, and relaxes cavernosal smooth muscle [10]. When you stop using the drug, your baseline erectile function returns to whatever it was before. There is no pharmacological penalty for stopping.

There may be a psychological penalty. Men who rely on alprostadil for sexual confidence and then stop abruptly sometimes report heightened performance anxiety, which functionally worsens their ED beyond baseline. This is a behavioral loop, not a pharmacological one.

Fibrosis Risk With Long-Term Use

Extended use of intracavernosal injections carries a small risk of corporal fibrosis (scar tissue in the cavernosa) that can reduce erection quality over time. A study by Levine and Dimitriou in Urology (N=177, follow-up 12 to 48 months) found palpable nodules in 5 to 8% of long-term Caverject users [11]. Rotating injection sites and using the lowest effective dose reduces this risk. MUSE avoids it entirely.

Laboratory Monitoring

No routine labs are required specifically for alprostadil. However, addressing underlying ED causes, testosterone deficiency, uncontrolled diabetes, cardiovascular disease, improves outcomes and may allow dose reduction. The Endocrine Society guideline on male hypogonadism recommends testosterone measurement before initiating any ED pharmacotherapy [12].

Restarting Alprostadil After a Break

Why Patients Come Back

Men who stop alprostadil and later restart most commonly do so after failing an alternative. They may have tried a PDE5 inhibitor, found it insufficient, and returned. Or they stopped because of a side effect that was actually dose-related and can be corrected. The most productive restarts follow a structured clinical conversation rather than simply resuming the previous prescription at the previous dose.

How to Restart Safely

Restart after a break of more than 6 months should involve in-office titration from a lower dose, even if the prior tolerated dose was higher. Tissue sensitivity does not change dramatically, but technique often drifts during the break. Restarting at a lower dose and titrating up during a supervised visit catches errors in injection site selection and angle before they become habit.

The recommended restart sequence for Caverject, per standard urology practice and consistent with FDA labeling [4]:

• Neurogenic ED: start at 1.25 mcg, titrate by 1.25 mcg increments
• Vasculogenic or mixed ED: start at 2.5 mcg, titrate by 2.5 to 5 mcg increments
• Maximum recommended dose: 60 mcg per injection, no more than 3 doses per week, with at least 24 hours between doses

Switching Delivery Routes at Restart

Some men restart by switching from Caverject to MUSE or vice versa. The switch from injection to suppository is logical for men whose primary barrier was needle anxiety. The switch from MUSE to Caverject is logical for men who found MUSE insufficiently effective. A head-to-head comparison by Shabsigh et al. In Urology found intracavernosal alprostadil produced superior rigidity scores compared with intraurethral alprostadil across all vasculogenic ED subtypes [13].

Combination therapy, specifically MUSE used alongside a constriction ring, improves MUSE efficacy meaningfully. The constriction ring increases penile venous resistance and sustains the erection produced by urethral absorption. Padma-Nathan's trial group reported a 61% intercourse success rate with this combination vs. 43% with MUSE alone [3].

Combining Alprostadil With PDE5 Inhibitors

Off-label combination of low-dose intracavernosal alprostadil with a PDE5 inhibitor (sildenafil 50 mg or tadalafil 5 mg) is used in clinical practice for men who respond partially to each agent alone. A randomized crossover study by Nehra et al. In the Journal of Urology (N=20 men, all post-radical prostatectomy) found that the combination produced superior erections to either agent alone, with no serious adverse events at the doses used [14]. This approach requires physician supervision because additive hypotension is possible.

Psychological Support as Part of Restart

Restarting alprostadil is more likely to succeed when the patient and, where relevant, partner are included in the clinical conversation before the first re-dose. The International Society for Sexual Medicine (ISSM) guidelines on sexual dysfunction management emphasize that psychosexual counseling alongside pharmacotherapy produces higher long-term adherence rates than pharmacotherapy alone [15].

Dose-Response and Titration Data

Alprostadil's dose-response curve is relatively steep in the 5 to 20 mcg range for most men with vasculogenic ED. A dose-ranging study by Linet and Ogrinc in The New England Journal of Medicine (N=296) showed that 4.7% of men responded to 2.5 mcg, 57.9% responded to 10 mcg, and 73.7% responded to 20 mcg, defined as an erection sufficient for intercourse [16]. Men who try the drug at 5 mcg and call it a failure are experiencing a titration problem, not a drug failure.

The practical implication: a man who tried Caverject once at 5 mcg, got a partial response, and stopped is a good candidate for restart with methodical titration to 10 to 20 mcg under physician guidance.